Sharda Cropchem Q2 Review- Raw Material Price Inflation To Weigh On Margins In Near To Mid-Term: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sharda Cropchem Ltd. reported consolidated earnings above our estimates. Sales grew by 51.3% YoY to Rs 6.4 billion (our estimate: Rs 4.6 billion) which came on the back of strong volume growth across geographies.
Revenue growth of 51.3% was a combination of 60.8% volume growth, 1.1% forex gain while there was a negative product mix impact of 10.6%.
Sharda Cropchem's gross margins took a hit falling 309 basis points YoY to 28% in Q2 FY22 owing to increase in prices of technicals which are largely imported from China.
Ebitda margins saw a 106 basis points contraction to 14.0% on the back of higher other expenses (up 30.9% YoY) and higher employee costs (up 42.2% YoY).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.